BASi Signs Preferred Provider Agreement With G1 Therapeutics

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) announced today that it has entered into a Preferred Provider Agreement (PPA) with G1 Therapeutics, a privately held company that develops small molecule therapeutics to protect bone marrow from damage due to chemotherapy or radiation. Under the agreement, BASi will become the preferred provider of preclinical services, including toxicology, bioanalytical and analytical testing, to support G1’s drug development programs.

Help employers find you! Check out all the jobs and post your resume.